CoChat

Gene Expression–Based Recurrence Prediction of Hepatitis B Virus–Related Human Hepatocellular Carcinoma

Open access
Woo, Hyun Goo, Park, Eun Sung, Cheon, Jae Hee, Kim, Ju Han, Lee, Ju-Seog, Park, Bum Joon, Kim, Won, Park, Su Cheol, Chung, Young Jin, Kim, Byeong Gwan, Yoon, Jung-Hwan, Lee, Hyo-Suk, Kim, Chung Yong, Yi, Nam-Joon, Suh, Kyung-Suk, Lee, Kuhn Uk, Chu, In-Sun, Roskams, Tania, Thorgeirsson, Snorri S., Kim, Yoon Jun · 2008 · Clinical Cancer Research

Published version of a preprint

Cited by 157

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Purpose: The poor prognosis of hepatocellular carcinoma (HCC) is, in part, due to the high rate of recurrence even after “curative resection” of tumors. Therefore, it is axiomatic that the development of an effective prognostic prediction model for HCC recurrence after surgery would, at minimum, help to identify in advance those who would most benefit from the treatment, and at best, provide new therapeutic strategies for patients with a high risk of early recurrence. Experimental Design: For the prediction of the recurrence time in patients with HCC, gene expression profiles were generated in 65 HCC patients with hepatitis B infections. Result: Recurrence-associated gene expression signatures successfully discriminated between patients at high-risk and low-risk of early recurrence (P = 1.9 × 10−6, log-rank test). To test the consistency and robustness of the recurrence signature, we validated its prognostic power in an independent HCC microarray data set. CD24 was identified as a putative biomarker for the prediction of early recurrence. Genetic network analysis suggested that SP1 and peroxisome proliferator–activated receptor-α might have regulatory roles for the early recurrence of HCC. Conclusion: We have identified a gene expression signature that effectively predicted early recurrence of HCC independent of microarray platforms and cohorts, and provided novel biological insights into the mechanisms of tumor recurrence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-07-1473

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 46

  1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–50. · DOI · Paper page
  2. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000;232:10–24. · DOI · Paper page
  3. Hanazaki K, Kajikawa S, Shimozawa N, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg 2000;191:381–8. · DOI · Paper page
  4. Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007;141:196–202. · DOI · Paper page
  5. Tsai TJ, Chau GY, Lui WY, et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000;127:603–8. · doi:10.1067/msy.2000.105498
  6. Zhou L, Rui JA, Wang SB, et al. Clinicopathological features, post-surgical survival and prognostic indicators of elderly patients with hepatocellular carcinoma. Eur J Surg Oncol 2006;32:767–72. · doi:10.1016/j.ejso.2006.03.050
  7. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500–7. · DOI · Paper page
  8. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918–28. · DOI · Paper page
  9. Llovet JM, Bruix J. Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;32:679–80. · DOI
  10. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207–15. · DOI · Paper page
  11. Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004;127:S126–32. · doi:10.1053/j.gastro.2004.09.026
  12. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–17. · DOI · Paper page
  13. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667–76. · DOI · Paper page
  14. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410–6. · DOI · Paper page
  15. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416–23. · DOI · Paper page
  16. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99–111. · DOI · Paper page
  17. Tinker AV, Boussioutas A, Bowtell DD. The challenges of gene expression microarrays for the study of human cancer. Cancer Cell 2006;9:333–9. · DOI
  18. Bammler T, Beyer RP, Bhattacharya S, et al. Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods 2005;2:351–6. · DOI · Paper page
  19. Hanazaki K, Matsushita A, Nakagawa K, Misawa R, Amano J. Risk factors of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatogastroenterology 2005;52:580–6.
  20. Inayoshi J, Ichida T, Sugitani S, et al. Gross appearance of hepatocellular carcinoma reflects E-cadherin expression and risk of early recurrence after surgical treatment. J Gastroenterol Hepatol 2003;18:673–7. · DOI
  21. Hanazaki K, Matsushita A, Nakagawa K, Misawa R, Amano J. Risk factors of long-term survival and recurrence after curative resection of hepatocellular carcinoma. Hepatogastroenterology 2005;52:552–7.
  22. Zhou L, Hayashi Y, Itoh T, Wang W, Rui J, Itoh H. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma. Pathol Int 2000;50:392–7. · DOI
  23. Itoh T, Hayashi Y, Kanamaru T, et al. Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15:422–30. · DOI
  24. Huang X, Yu C, Jin C, et al. Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis. Cancer Res 2006;66:1481–90. · DOI
  25. Hu L, Lau SH, Tzang CH, et al. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 2004;23:298–302. · DOI · Paper page
  26. Gotzmann J, Fischer AN, Zojer M, et al. A crucial function of PDGF in TGF-β-mediated cancer progression of hepatocytes. Oncogene 2006;25:3170–85. · DOI · Paper page
  27. Yasuda S, Arii S, Mori A, et al. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1α and its significance. J Hepatol 2004;40:117–23. · DOI
  28. Baumann P, Cremers N, Kroese F, et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 2005;65:10783–93. · DOI · Paper page
  29. Kristiansen G, Winzer KJ, Mayordomo E, et al. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003;9:4906–13.
  30. Su MC, Hsu C, Kao HL, Jeng YM. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett 2006;235:34–9. · doi:10.1016/j.canlet.2005.03.059
  31. Kristiansen G, Pilarsky C, Pervan J, et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004;58:183–92. · DOI
  32. Sagiv E, Memeo L, Karin A, et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 2006;131:630–9. · DOI
  33. Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, Petersen I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 2003;88:231–6. · DOI · Paper page
  34. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002;161:1215–21. · DOI · Paper page
  35. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004;127:S113–9. · DOI · Paper page
  36. Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 2005;41:2438–48. · DOI · Paper page
  37. Abdelrahim M, Smith R III, Burghardt R, Safe S. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 2004;64:6740–9. · DOI · Paper page
  38. Zannetti A, Del Vecchio S, Carriero MV, et al. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 2000;60:1546–51.
  39. Yao JC, Wang L, Wei D, et al. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004;10:4109–17. · DOI · Paper page
  40. Peters JM, Cheung C, Gonzalez FJ. Peroxisome proliferator-activated receptor-α and liver cancer: where do we stand? J Mol Med 2005;83:774–85. · DOI · Paper page
  41. Gonzalez FJ. The peroxisome proliferator-activated receptor α (PPARα): role in hepatocarcinogenesis. Mol Cell Endocrinol 2002;193:71–9. · DOI
  42. Gervois P, Torra IP, Chinetti G, et al. A truncated human peroxisome proliferator-activated receptor α splice variant with dominant negative activity. Mol Endocrinol 1999;13:1535–49. · DOI
  43. Grabacka M, Plonka PM, Urbanska K, Reiss K. Peroxisome proliferator-activated receptor α activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res 2006;12:3028–36. · DOI
  44. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 2005;24:1809–19. · DOI
  45. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003;38:756–68. · DOI · Paper page
  46. Gold LI. The role for transforming growth factor-β (TGF-β) in human cancer. Crit Rev Oncog 1999;10:303–60.

Cited by

See all 157

Metadata

Authors
Woo, H. G., Park, E. S., Cheon, J. H., Kim, J. H., Lee, J.-S., Park, B. J., Kim, W., Park, S. C., Chung, Y. J., Kim, B. G., Yoon, J.-H., Lee, H.-S., Kim, C. Y., Yi, N.-J., Suh, K.-S., Lee, K. U., Chu, I.-S., Roskams, T., Thorgeirsson, S. S., & Kim, Y. J.
Venue
Clinical Cancer Research
Published
2008-04-01
Volume
14
Issue
7
Pages
2056-2064
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2101937389
Cited by
157
References
2
FWCI
8.89
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene Expression–Based Recurrence Prediction of Hepatitis B Virus–Related Human Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-1473
The paper
Woo, H. G., Park, E. S., Cheon, J. H., Kim, J. H., Lee, J.-S., Park, B. J., Kim, W., Park, S. C., Chung, Y. J., Kim, B. G., Yoon, J.-H., Lee, H.-S., Kim, C. Y., Yi, N.-J., Suh, K.-S., Lee, K. U., Chu, I.-S., Roskams, T., Thorgeirsson, S. S., & Kim, Y. J. (2008). Gene Expression–Based Recurrence Prediction of Hepatitis B Virus–Related Human Hepatocellular Carcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-1473

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.